Amoxicillin is a semi–synthetic broad-spectrum antibiotic with activity against many Gram-positive and Gram-negative microorganisms. At the same time, amoxicillin is susceptible to degradation by beta-lactamases, and therefore the spectrum of activity of amoxicillin does not extend to microorganisms that produce these enzymes.
Clavulanic acid, a beta–lactamase inhibitor structurally related to penicillins, has the ability to inactivate a wide range of beta-lactamases found in microorganisms resistant to penicillins and cephalosporins. Clavulanic acid is sufficiently effective against plasmid beta-lactamases, which most often cause bacterial resistance.

The drug Amklav® is indicated for adults and children aged 0 to 18 years.
The combination of amoxicillin with clavulanic acid is indicated for treatment bacterial infections of the following locations caused by
sensitive to the combination of amoxicillin with clavulanic acid
by microorganisms:

• upper respiratory tract infections (including ENT infections), for example, recurrent tonsillitis, sinusitis, otitis media, usually caused by Streptococcus pneumoniae, Haemophilus influenzae*, Moraxella catarrhalis* and Streptococcus pyogenes;
• lower respiratory tract infections, for example, exacerbation of chronic bronchitis, lobular pneumonia and bronchopneumonia, usually caused by Streptococcus pneumoniae, Haemophilus influenzae*, Moraxella catarrhalis*;
• infections of the genitourinary tract, for example, cystitis, urethritis, pyelonephritis, infections of the female genital organs, usually caused by species of the family Enterobacteriaceae* (mainly Escherichia coli*), Staphylococcus saprophyticus and species of the genus Enterococcus, as well as gonorrhea caused by Neisseria gonorrhoeae*;
• infections of the skin and soft tissues (including human and animal bites), usually caused by Staphylococcus aureus*, Streptococcus pyogenes and species of the genus Bacteroides*;
• infections of bones and joints, for example, osteomyelitis, usually caused by Staphylococcus aureus*, if necessary, long-term therapy is possible;
• other mixed infections (e.g. septic abortion,
• postpartum sepsis, intra-abdominal sepsis, sepsis, peritonitis,
• postoperative infections) as part of step-by-step therapy;
• the drug Amklav® in a dosage of 1000 mg + 200 mg is also indicated for the prevention of postoperative infections, during surgical interventions on the gastrointestinal tract, pelvic organs, head and neck, heart, kidneys, biliary tract, as well as
• artificial joint implantation.

There may be symptoms from the gastrointestinal tract and disorders of the water-electrolyte balance. Amoxicillin crystalluria has been described, which in some cases led to the development of renal failure.
Seizures may occur in patients with impaired renal function, as well as in those who receive high doses of the drug.
After intravenous administration of large doses of amoxicillin, it can precipitate in urinary catheters. Therefore, regular checking of the patency of urinary catheters should be carried out.

The most common adverse reactions are diarrhea, candidiasis of the skin and mucous membranes.

Hypersensitivity to amoxicillin, clavulanic acid, penicillins, and other components of the drug in the anamnesis

• History of severe hypersensitivity reactions (e.g., anaphylaxis) to other beta-lactam antibiotics (e.g., cephalosporins, carbapenems, monobactams)
• Previous episodes of jaundice or impaired liver function when using a combination of amoxicillin with clavulanic acid in the anamnesis

Simultaneous use of Amklav® and probenecid is not recommended.
Probenecid reduces the tubular secretion of amoxicillin, and therefore the simultaneous use of Amclav® and probenecid may lead to an increase in the concentration and persistence of amoxicillin in the blood, but not clavulanic acid.
Simultaneous use of allopurinol and amoxicillin may increase the risk of allergic skin reactions. Currently, there is no data in the literature on the simultaneous use of a combination of amoxicillin with clavulanic acid and allopurinol.
Penicillins can slow the elimination of methotrexate from the body by inhibiting its renal tubular secretion, therefore, the simultaneous use of Amclav® and methotrexate may increase the toxicity of methotrexate.

Registration certificate holder
JSC Biochemist, Russian Federation
15A Vasenko St., Saransk, Republic of Mordovia, 430030
Manufacturer
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: +7 (8342) 38 03 68
Email: biohimic@promomed.pro
Internet address: promomed.ru
An organization that accepts consumer claims
JSC Biochemist, Russian Federation
Address: 15A Vasenko str., Saransk, 430030, Republic of Mordovia
Phone number: 8 800 222 95 63; 8 800 777 86 04 ( around the clock)
Email: hot_line@promomed.pro

2 years. Do not use after the expiration date.

Store at a temperature not exceeding 25 ° C. Store in the original packaging (pack/box). Keep out of reach of children.

They are available on prescription.